This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jacobio Pharmaceuticals Group Co., Ltd. commences an Equity Buyback Plan for 79,175,508 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024. CI
Jacobio Pharmaceuticals Group Co., Ltd.'s Equity Buyback announced on July 24, 2023, has expired. CI
Hong Kong Stocks Rebound Following More than Expected Growth in China’s Manufacturing Sector MT
Jacobio Pharmaceuticals Presents Data on Lung Cancer Treatment at US Oncology Meet; Shares Surge 12% MT
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO CI
Jacobio Pharmaceuticals Group's Lung Cancer Drug Get NDA from China's NMPA MT
Jacobio Pharmaceuticals Group Co., Ltd. Announces New Drug Application for Its Independently Developed Novel KRAS G12C Inhibitor Glecirasib (Jab-21822) CI
Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab MT
Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer CI
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22% MT
Jacobio Pharmaceuticals Group Co., Ltd. Announces Submission of New Drug Application for KRAS G12C Inhibitor Glecirasib (JAB-21822) CI
Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint CI
Jacobio Pharmaceuticals Plans Auditor Change MT
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention MT
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting CI
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses MT
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jacobio Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Clinical Trial for Anti-Tumor Drug; Shares Surge 16% MT
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300 CI
Hong Kong Stocks Fall as Chinese Central Bank Leaves Key Policy Rate on Hold; Jacobio Falls 11% Despite Drug Progress MT
China Approves Jacobio's Phase 3 Trial of Non-Small Cell Lung Cancer Drug; Shares Plummet 13% MT
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor CI
Jacobio Presents Clinical Data on Pancreatic Cancer Treatment at Oncology Meet; Shares Fall 7% MT
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI CI
Jacobio to Present Clinical Results of Pancreatic Cancer Drug in US Meet; Shares Jump 3% MT
Chart Jacobio Pharmaceuticals Group Co., Ltd.
More charts
Jacobio Pharmaceuticals Group Co Ltd is a China-based investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly conducts business within the domestic market.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.644 CNY
Average target price
3.954 CNY
Spread / Average Target
+140.51%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 1167 Stock
  4. News Jacobio Pharmaceuticals Group Co., Ltd.
  5. Jacobio Pharmaceuticals to Present Data on Anti-Tumor Combination Therapy in Spain